Study to Evaluate the Safety and Efficacy of SCH 530384 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: thrombin Receptor Antagonist i Secondary Prevention of Atherothrombotic Ischemic Events
Description of Research
The purpose of the study is to test the safety and effectiveness of an investigational drug that blocks platelets and may reduce the risk of heart attack or stroke, when used with standard medications that your doctor has decided you will receive for treatment of your atherosclerosis.
Subject may be of either sex and any race, and must be at least 18 years old.
Subject must have evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems